Early Detection of Intracardiac Blood Clots Using 64CuFBP8 PETMRI in Adults with Cardiac Amyloidosis and Atrial Fibrillation or Flutter

What this Trial Is About

Researchers are evaluating a new imaging technique using 64CuFBP8, a novel fibrin-binding PET probe combined with simultaneous cardiac PETMRI, to detect intracardiac blood clots in people with transthyretin or light chain cardiac amyloidosis who also have atrial fibrillation or atrial flutter. This pilot study aims to see if the imaging can identify clots in over 90% of patients who have confirmed clots based on a standard transesophageal echocardiogram TEE. Secondary analyses will explore how these clots relate to heart function and amyloid build-up in the left ventricle. Participants will receive an injection of 64CuFBP8 followed by simultaneous cardiac PETMR imaging. The study involves twenty individuals with documented cardiac amyloidosis and atrial fibrillation or flutter. The imaging is performed once, and results will be compared to recent or upcoming TEE tests to confirm the presence of clots. This study focuses on evaluating the diagnostic value of this new PETMRI method in detecting intracardiac thrombi. During the study, participants will undergo PETMR imaging after receiving the tracer injection. The main outcome measured is the detection of intracardiac thrombus within one day of imaging. The researchers will also assess associations between clots and heart function or amyloid burden. Participants will be monitored for eligibility and safety, including assessments of their ability to undergo imaging and recent heart evaluations. The study is expected to last from July 2026 to March 2027, with diagnostic imaging as the key procedure.

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy